Abstracts tagged "outcome measures and psoriatic arthritis"

Abstract Number: 1606 • 2018 ACR/ARHP Annual Meeting
The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative
Ali Duarte-Garcia¹, Lihi Eder², Niti Goel³, Robin Christensen⁴, Maarten de Wit⁵, Oliver FitzGerald⁶, Dafna D Gladman⁷, Richard Holland⁸, Ying Ying Leung⁹, Christine Lindsay¹⁰, Neil McHugh¹¹, Philip J. Mease¹², Ana-Maria Orbai¹³, Beverly Shea¹⁴, Vibeke Strand¹⁵, William Tillett¹⁶, Laura C. Coates¹⁷ and Alexis Ogdie¹⁸, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ³Kezar Life Sciences; Duke University School of Medicine, Durham, NC, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ⁵EULAR standing committee of PARE, Zurich, Switzerland, ⁶Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Royal Prince Alfred Hospital Medical Centre, Sydney, Australia, ⁹North District Hospital, Hong Kong, China, ¹⁰Medical Affairs, Amgen Inc, Thousand Oaks, CA, ¹¹Rheumatology, Royal National Hospital, Bath, Great Britain, ¹²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Stanford University School of Medicine, Palo Alto, CA, ¹⁶Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, ¹⁷University of Oxford, Oxford, United Kingdom, ¹⁸Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: A psoriatic arthritis (PsA) core domain set to be measured in randomized controlled trials (RCT) and longitudinal observational studies (LOS) was developed by Group…
Abstract Number: 641 • 2018 ACR/ARHP Annual Meeting
Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis
Ali Duarte-Garcia¹, Lihi Eder², Alisa Stephens-Shields³, Niti Goel⁴, Maarten de Wit⁵, Dafna D Gladman⁶, Oliver FitzGerald⁷, Philip Helliwell⁸, Ying Ying Leung⁹, Philip J. Mease¹⁰, Ana-Maria Orbai¹¹, Beverly Shea¹², Vibeke Strand¹³, William Tillett¹⁴, Laura C. Coates¹⁵ and Alexis Ogdie¹⁶, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ³Department of Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Kezar Life Sciences; Duke University School of Medicine, Durham, NC, ⁵EULAR standing committee of PARE, Zurich, Switzerland, ⁶Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁸LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁹North District Hospital, Hong Kong, China, ¹⁰Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ¹¹Johns Hopkins University School of Medicine, Baltimore, MD, ¹²University of Ottawa, Ottawa, ON, Canada, ¹³Stanford University School of Medicine, Palo Alto, CA, ¹⁴Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, ¹⁵University of Oxford, Oxford, United Kingdom, ¹⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Joint counts are central to the measurement of musculoskeletal disease activity in psoriatic arthritis (PsA). Few studies have addressed whether the three most commonly…
Abstract Number: 650 • 2018 ACR/ARHP Annual Meeting
Can Disease Activity in Patients with Psoriatic Arthritis be Adequately Assessed By a Modified Disease Activity Index for Psoriatic Arthritis (DAPSA) Based on 28 Joints?
Brigitte Michelsen^1,2, Joseph Sexton¹, Josef S. Smolen³, Daniel Aletaha⁴, Niels Steen Krogh⁵, Désirée van der Heijde⁶, Tore Kvien⁷ and Merete Lund Hetland^8,9, ¹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Division of Rheumatology, Department of Internal Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Leiden University Medical Centre, Leiden, Netherlands, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, The DANBIO Registry, Glostrup, Denmark, ⁹University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Many registries routinely collect only 28 joint count, although 66/68 joint count has higher face validity in PsA. We aimed to compute and test…
Abstract Number: 1406 • 2018 ACR/ARHP Annual Meeting
Longitudinal Construct Validity of the Psaid Individual Items: Can We Eliminate Other Questionnaires If Using the Psaid?
Jessica Walsh¹, Jose U. Scher², Soumya M. Reddy³, M. Elaine Husni⁴ and Alexis Ogdie⁵, ¹University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ²New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ⁵Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Psoriatic Arthritis Impact of Disease (PsAID) questionnaire is a patient reported measure of disease impact. The 12-item questionnaire has many advantages including demonstrated…
Abstract Number: 1805 • 2017 ACR/ARHP Annual Meeting
Construct Validity of RAPID3 for Measurement of Disease Activity in Psoriatic Arthritis
Jessica A. Walsh¹, Christine Willinger², M. Elaine Husni³, Soumya M. Reddy⁴, Jose U. Scher⁵ and Alexis Ogdie⁶, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²University of Pennsylvania, Philadelphia, PA, ³Cleveland Clinic, Cleveland, OH, ⁴Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Routine Assessment of Patient Index Data (RAPID3) was developed and validated for rheumatoid arthritis (RA). Little data exist on the use of RAPID3…
Abstract Number: 2039 • 2017 ACR/ARHP Annual Meeting
Validity of the Wpai-SHP in Psoriatic Arthritis and Estimation of the Minimally Important Difference
William Tillett^1,2, Gavin Shaddick³, Bashaar Boyce⁴ and Neil J. McHugh⁵, ¹Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, ³Centre for Data Science and Statistics, University of Exeter, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom
Background/Purpose: Participation, including work disability, is an important patient centred outcome and is in the middle ring of the Outcome Measures in Rheumatology (OMERACT) psoriatic…
Abstract Number: 2245 • 2017 ACR/ARHP Annual Meeting
The Effects of Structural Damage on Functional Disability in Psoriatic Arthritis
Andreas Kerschbaumer¹, Gabriela Supp¹, Josef S. Smolen^1,2 and Daniel Aletaha¹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
Background/Purpose: Functional outcomes are central in patients with chronic inflammatory musculoskeletal diseases. In a secondary data analysis of the GO-REVEAL trial we investigated if structural…
Abstract Number: 2971 • 2017 ACR/ARHP Annual Meeting
What Do Reduced 28 Joint Counts Miss in Patients with Psoriatic Arthritis?
Andreas Kerschbaumer¹, Josef S. Smolen^1,2 and Daniel Aletaha¹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
Background/Purpose: Clinical joint assessment by the rheumatologist is a key examination of patients with psoriatic arthritis (PSA). A clinically swollen joint is predicting subsequent joint…
Abstract Number: 2742 • 2016 ACR/ARHP Annual Meeting
How Are Enthesitis, Dactylitis and Nail Involvement Measured and Reported in Recent Clinical Trials of Psoriatic Arthritis (PsA)? a Systematic Literature Review
Sofia Ramiro¹, Josef Smolen², RBM Landewé³, Désirée van der Heijde⁴ and Laure Gossec⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France
Background/Purpose: Enthesitis, dactylitis and nail involvement are part of the core set of domains to be reported in trials of PsA. However, no specific instruments…
Abstract Number: 549 • 2014 ACR/ARHP Annual Meeting
Reliability and Construct Validity of the Psoriasis Symptom Inventory in Subjects with Psoriatic Arthritis
Philip J. Mease¹, Mark C. Genovese², Alex Mutebi³, Hilary Wilson⁴, Dennis Revicki⁴, Ngozi Erondu⁵, Ajay Nirula⁵, JingYuan Feng⁵ and Hema Viswanathan⁶, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³Global Health Economics, Amgen Inc, Thousand Oaks, CA, ⁴Outcomes Research, Evidera, Bethesda, MD, ⁵Amgen Inc, Thousand Oaks, CA, ⁶Amgen Inc, Amgen Inc, Thousand Oaks, CA
Background/Purpose: The Psoriasis Symptom Inventory (PSI) is an 8-item patient-reported outcome measure of psoriasis symptom severity. Data from a Phase 2 study of Brodalumab in…
Abstract Number: 347 • 2013 ACR/ARHP Annual Meeting
Factors Explaining The Discrepancy Between Patient and Physician Global Assessment Of Disease Activity In Psoriatic Arthritis
Lihi Eder¹, Arane Thavaneswaran¹, Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Patients and physicians often perceive the extent of disease activity differently. We aimed to assess the factors contributing to the variability in scoring of…
Abstract Number: 1833 • 2012 ACR/ARHP Annual Meeting
Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate
Frank Zhang¹, Robert Hiscock² and Jeffrey R. Curtis³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²Analysis Group, Inc., Montreal, QC, Canada, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Several treatment options are available for psoriatic arthritis (PsA) patients (pts). The healthcare cost associated with the management of PsA pts varies depending on…
Abstract Number: 535 • 2012 ACR/ARHP Annual Meeting
Reduced Joint Counts Misclassify Psoriatic Arthritis Patients with Oligoarthritis and Miss Significant Active Disease
Laura C. Coates¹, Oliver FitzGerald², Dafna D. Gladman³, Neil J. McHugh⁴, Philip J. Mease⁵, Vibeke Strand⁶, Philip S. Helliwell⁷ and GRAPPA Composite Exercise (GRACE) collaboration⁸, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Dept of Rheumatology, St. Vincent's Univ Hospital, Dublin, Ireland, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁶Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ⁷PsAID taskforce, EULAR, Zurich, Switzerland, ⁸Leeds
Background/Purpose: Despite recommendations to use full joint counts to assess patients with PsA, reduced joint counts designed for RA are often used for reporting outcomes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].